> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Heart Failure Drug
- URL: https://www.fdaweb.com/panel-to-discuss-heart-failure-drug/
- Published: 2022-10-05T12:00:00.000Z
- Updated: 2026-09-14T18:02:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152894

*Federal Register* notice: FDA has announced a 12/13 Cardiovascular and Renal Drugs Advisory Committee meeting to review a Cytokinetics NDA for omecamtiv mecarbil tablets, indicated to reduce the risk of cardiovascular death and heart failure events in patients with symptomatic chronic heart failure with reduced ejection fraction. Panel members will discuss whether a Phase 3 trial (GALACTIC-HF) establishes substantial evidence of effectiveness and whether the benefits of omecamtiv mecarbil outweigh the risks when used according to the applicant’s proposed dosing regimen. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-21769.pdf?ref=fdaweb.com).